Drugs / leuproprolirelin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT06972511 Background | Aug 2023 → Dec 2025 overdue | metastatic prostate carcinoma | RenJi Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | leuproprolirelin | “leuproprolirelin 3.75mg subcutaneous injection once every month” NCT06972511 ↗ |
| Route | Subcutaneous | “leuproprolirelin 3.75mg subcutaneous injection once every month” NCT06972511 ↗ |